Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Darunavir/Cobicistat and Etravirine in HIV
NCT02818348Phase 1Completed
- Start
- Jun 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of darunavir, cobicistat and etravirine in human immunodeficiency virus type 1 infection (HIV-1) (2 cohorts). Primary endpoints: Darunavir, cobicistat and etravirine concentrations in plasma at Day 21 and Grade >=3 adverse events and serious adverse events at Day 35. Started Jun 2016; status: completed.
02
Drugs
darunavircobicistatetravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02818348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818348.